EGFR and non-small cell lung carcinoma: Our current study showed that methylation of Wnt antagonist SFRP5 gene before treatment, independent of the genotype of EGFR gene, correlated with decreased progression free survival rate in NSCLC patients in response to the EGFR-TKI therapy.